These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 14674706)

  • 1. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
    Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
    Mol Cell Biochem; 2003 Dec; 254(1-2):265-73. PubMed ID: 14674706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
    Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
    J Pharmacol Exp Ther; 2003 Apr; 305(1):97-105. PubMed ID: 12649357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
    Bäcklund T; Palojoki E; Saraste A; Grönholm T; Eriksson A; Lakkisto P; Vuolteenaho O; Nieminen MS; Voipio-Pulkki LM; Laine M; Tikkanen I
    Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W; Dominiak P; Dendorfer A
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
    Lapointe N; Blais C; Adam A; Parker T; Sirois MG; Gosselin H; Clément R; Rouleau JL
    J Am Coll Cardiol; 2002 May; 39(10):1692-8. PubMed ID: 12020499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
    Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
    Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure.
    Lapointe N; Tsoporis JN; Parker TG; Blais C; Adam A; Rouleau D; Slaughter G; Clément R; Deschepper CE; Rouleau JL
    Mol Cell Biochem; 2003 Dec; 254(1-2):235-45. PubMed ID: 14674703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats.
    Pu Q; Schiffrin EL
    Am J Hypertens; 2001 Oct; 14(10):1067-72. PubMed ID: 11710787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
    Sulpizio AC; Pullen MA; Edwards RM; Louttit JB; West R; Brooks DP
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM
    Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
    Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure.
    Burrell LM; Farina NK; Balding LC; Johnston CI
    Hypertension; 2000 Dec; 36(6):1105-11. PubMed ID: 11116133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
    Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK; Johnston CI; Burrell LM
    J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
    Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
    Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
    Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.